NICE NG28 advises considering a GLP-1 receptor agonist in preference to a sulphonylurea when weight loss or avoidance of hypoglycaemia is a priority, though sulphonylureas remain appropriate options in selected patients
As of now, there have not been direct head-to-head clinical studies comparing retatrutide and tirzepatide
In a Novo Nordisk funded study of 3,417 adults without diabetes and with a BMI of 30 or higher, or a BMI of 27 or higher with at least one obesity-related complication, participants achieved an average 20.4% weight loss with cagrilintidesemaglutide, compared with 3.0% with placebo 14
slowed during the quarter
C th tch t c t do ch n ung thiu khoa hc lm bn lun cm thy mt mi, u oi v h min dch suy gim r rt
Michaelson Jenet sees an active role for state governments in creating solutions